Ipratropium Export Market Intelligence: India's 173 Suppliers Shipping to 81 Countries — TransData Nexus 2026

Q: Who are the top ipratropium exporters from India?

The top ipratropium exporters from India are: 1. CIPLA LIMITED — $48.3M (84.7% market share); 2. AHLCON PARENTERALS (INDIA) LIMITED — $2.5M (4.4% market share); 3. SUN PHARMACEUTICAL INDUSTRIES LIMITED — $2.3M (4.0% market share); 4. ALTHEA PHARMA PRIVATE LIMITED — $685.5K (1.2% market share); 5. AHLCON PARENTERALS INDIA LIMITED — $431.7K (0.8% market share). Together they account for 95.0% of India's total ipratropium export value.

Q: What is the total export value of ipratropium from India?

The total export value of ipratropium from India is $57.1M USD, recorded across 2,297 shipment transactions from 173 active exporters to 81 destination countries. The average shipment value is $24.8K.

Q: Which countries import ipratropium from India?

India exports ipratropium to 81 countries worldwide. The top importing countries are: SOUTH AFRICA (55.2% share, $31.5M), UNITED STATES (28.5% share, $16.2M), PHILIPPINES (8.4% share, $4.8M), NEW ZEALAND (1.0% share, $588.8K), VENEZUELA (0.9% share, $526.8K). These five markets account for 94.0% of total export value.

Q: What is the HS code for ipratropium exports from India?

The primary HS code for ipratropium exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of ipratropium exports from India?

The average unit price for ipratropium exports from India is $9.01 USD per unit, with prices ranging from $0.01 to $11607.35 depending on formulation, packaging, and order volume. The total market is valued at $57.1M across 2,297 shipments.

Q: Which ports handle ipratropium exports from India?

The primary ports for ipratropium exports from India are SAHAR AIR (16.8% of shipments), SAHAR AIR CARGO ACC (INBOM4) (13.3% of shipments), DELHI AIR (10.1% of shipments), DELHI AIR CARGO ACC (INDEL4) (9.4% of shipments), NHAVA SHEVA SEA (INNSA1) (8.6% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of ipratropium?

India is one of the world's leading exporters of ipratropium due to its large base of 173 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports ipratropium to 81 countries, demonstrating 42% global market coverage.

Q: What certifications do Indian ipratropium exporters need?

Indian ipratropium exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import ipratropium from India?

There are 306 registered buyers importing ipratropium from India, spread across 81 countries. The repeat buyer rate is 58.8%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top ipratropium supplier from India?

CIPLA LIMITED is the leading ipratropium exporter from India with a market share of 84.7% and total export value of $48.3M across 402 shipments. The top 5 suppliers together control 95.0% of total export value.

Suresh Sormare

Ipratropium

India Pharmaceutical Trade Intelligence

$57.1M173 Suppliers81 CountriesHS 30049099

ExportsIndia → SOUTH AFRICA55.2%India → UNITED STATES28.5%

#1 Supplier: CIPLA LIMITED

Ipratropium Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Ipratropium to the World

Between 2022 and 2026, India exported $57.1M worth of ipratropium across 2,297 verified shipments to 81 countries — covering 42% of world markets in the Respiratory & OTC segment. The largest destination is SOUTH AFRICA (55.2%). CIPLA LIMITED leads with a 84.7% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·HS 30049099

Ipratropium export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Ipratropium export data snapshot — $57.1M · 173 exporters · 81 countriesTransData Nexus · Indian Customs Data

Top Ipratropium Exporters from India

173 active exporters · Ranked by export value

View all 173 →

Top Ipratropium Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	CIPLA LIMITED	$48.3M	402	19	84.7%
2	AHLCON PARENTERALS (INDIA) LIMITED

Top Countries Importing Ipratropium from India

81 destination markets · Ranked by import value

All 81 countries →

Top Countries Importing Ipratropium from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	SOUTH AFRICA	$31.5M	55.2%
2	UNITED STATES	$16.2M	28.5%
3	PHILIPPINES	$4.8M	8.4%
4	NEW ZEALAND	$588.8K	1.0%
5	VENEZUELA	$526.8K	0.9%
6	MALAYSIA	$474.4K	0.8%
7	YEMEN	$439.4K	0.8%
8	BELGIUM	$396.6K	0.7%
9	SRI LANKA	$376.8K	0.7%
10	LEBANON	$200.5K	0.4%

SOUTH AFRICA is India's largest ipratropium export destination, absorbing 55.2% of total exports worth $31.5M. The top 5 importing countries — SOUTH AFRICA, UNITED STATES, PHILIPPINES, NEW ZEALAND, VENEZUELA — together account for 94.0% of India's total ipratropium export value. The remaining 76 destination countries collectively receive the other 6.0%, indicating a broadly diversified export footprint across multiple regions.

Regulatory Landscape — Ipratropium

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, ipratropium bromide has been approved through both New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs). The FDA approved the first NDA for ipratropium bromide inhalation solution (NDA #75-111) on April 22, 1999, submitted by Alpharma U.S. Pharmaceuticals Division. Subsequently, multiple ANDAs have been approved, facilitating the entry of generic versions into the market. Notably, as of February 12, 2026, the FDA has not approved a generic version of Atrovent HFA, a specific formulation of ipratropium bromide.

The substantial export of ipratropium from India to the U.S., amounting to 28.5% of total exports, underscores the importance of compliance with FDA regulations. Indian manufacturers must adhere to stringent FDA requirements, including Good Manufacturing Practices (GMP), to ensure product quality and safety. The presence of 173 active Indian exporters indicates a competitive landscape, necessitating continuous regulatory vigilance to maintain market access.

2EU & UK Regulatory Framework

In the European Union (EU) and the United Kingdom (UK), ipratropium bromide is subject to marketing authorization by the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), respectively. The EMA has conducted periodic safety update report single assessments (PSUSAs) for ipratropium-containing products, such as the assessment completed on November 27, 2017. (ema.europa.eu) Additionally, the MHRA issued a Class 3 medicines recall for a batch of ipratropium bromide nebuliser solution on October 23, 2025, due to labeling issues. (gov.uk)

Compliance with EU and UK GMP requirements is mandatory for Indian exporters targeting these markets. This includes adherence to guidelines on manufacturing processes, quality control, and pharmacovigilance to ensure product safety and efficacy.

3WHO Essential Medicines & Global Standards

Ipratropium bromide is listed in the WHO Model List of Essential Medicines, highlighting its critical role in treating respiratory conditions. The inclusion in the 6th WHO Model List of Essential Medicines for Children, published in April 2017, further emphasizes its importance. (tdr.who.int) Indian manufacturers exporting ipratropium must ensure compliance with international pharmacopoeia standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to meet global quality expectations.

4India Regulatory Classification

In India, ipratropium bromide is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing to ensure affordability. Exporting ipratropium requires a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national export regulations.

5Patent & Exclusivity Status

The primary patents for ipratropium bromide have expired, allowing for generic competition. However, certain formulation and device patents, such as the inhaler device patent (US8474447), remain active until January 2030. This ongoing patent protection may influence market dynamics and the entry of new generic formulations.

6Recent Industry Developments

In October 2025, the MHRA issued a Class 3 medicines recall for a batch of ipratropium bromide nebuliser solution due to labeling discrepancies, underscoring the importance of stringent quality control measures. (gov.uk)

Additionally, as of February 12, 2026, the FDA has not approved a generic version of Atrovent HFA, indicating ongoing market exclusivity for this formulation.

These developments highlight the necessity for Indian exporters to maintain rigorous compliance with international regulatory standards to ensure continued market access and competitiveness.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Ipratropium

Retail & reference prices across 9 markets vs. India FOB export price of $9.01/unit

Global Price Benchmark for Ipratropium across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$0.18	USD	According to the FDA's Orange Book, ipratropium bromide inhalation solutions are approved for therapeutic use.
United Kingdom	$0.17	GBP	The NHS Drug Tariff lists ipratropium bromide inhalation solutions as available for prescription.
Germany	$0.16	EUR	The Federal Institute for Drugs and Medical Devices (BfArM) includes ipratropium bromide inhalation solutions in its approved medicinal products.
Australia	$0.18

Supply Chain Risk Assessment — Ipratropium

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

Ipratropium, a bronchodilator used in the treatment of respiratory conditions, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) often relies on Key Starting Materials (KSMs) sourced from China. This dependency exposes the supply chain to potential disruptions stemming from geopolitical tensions, trade restrictions, or production issues within China. For instance, a 2025 study by the U.S. Pharmacopeia highlighted that 41% of KSMs used in U.S.-approved medicines are sourced solely from China, underscoring the vulnerability of pharmaceutical supply chains to such concentrated sourcing.

Recent events have further exacerbated these risks. In February 2026, escalating conflicts in the Middle East led to the effective shutdown of the Strait of Hormuz, a critical maritime chokepoint. This disruption has significantly impacted the transportation of raw materials, including those essential for pharmaceutical manufacturing, causing delays and potential shortages in API production.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data from 2022 to 2026 reveals a high concentration in the export of Ipratropium from India. The top five exporters account for 95.0% of the total export value, with CIPLA LIMITED alone contributing 84.7% ($48.3 million USD). This significant concentration poses a single-source risk; any operational or regulatory issues affecting CIPLA LIMITED could disrupt the global supply of Ipratropium.

Access Complete Ipratropium Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 2,297 transactions across 81 markets.

Request Demo View Pricing

Frequently Asked Questions — Ipratropium Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top ipratropium exporters from India?

The leading ipratropium exporters from India are CIPLA LIMITED, AHLCON PARENTERALS (INDIA) LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, and 11 others. CIPLA LIMITED leads with 84.7% market share ($48.3M). The top 5 suppliers together control 95.0% of total export value.

What is the total export value of ipratropium from India?

The total export value of ipratropium from India is $57.1M, recorded across 2,297 shipments from 173 active exporters to 81 countries. The average shipment value is $24.8K.

Which countries import ipratropium from India?

India exports ipratropium to 81 countries. The top importing countries are SOUTH AFRICA (55.2%), UNITED STATES (28.5%), PHILIPPINES (8.4%), NEW ZEALAND (1.0%), VENEZUELA (0.9%), which together account for 94.0% of total export value.

What is the HS code for ipratropium exports from India?

The primary HS code for ipratropium exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Ipratropium

Ipratropium

How India Exports Ipratropium to the World

Top Ipratropium Exporters from India

Top Countries Importing Ipratropium from India

Quick Facts

Related Respiratory & OTC

Related Analysis

Need Details?

Regulatory Landscape — Ipratropium

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Ipratropium

Supply Chain Risk Assessment — Ipratropium

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Ipratropium Trade Intelligence

Frequently Asked Questions — Ipratropium Exports from India

Who are the top ipratropium exporters from India?

What is the total export value of ipratropium from India?

Which countries import ipratropium from India?

What is the HS code for ipratropium exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of ipratropium exports from India?

Which ports handle ipratropium exports from India?

Why is India a leading exporter of ipratropium?

What certifications do Indian ipratropium exporters need?

How many buyers import ipratropium from India?

What is the market share of the top ipratropium exporter from India?

Analysis Methodology